Arizona State Retirement System Purchases Shares of 12,099 G1 Therapeutics, Inc. (NASDAQ:GTHX)

Arizona State Retirement System purchased a new position in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,099 shares of the company’s stock, valued at approximately $66,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Fox Run Management L.L.C. bought a new position in G1 Therapeutics during the 4th quarter worth $128,000. Envestnet Asset Management Inc. bought a new stake in G1 Therapeutics during the 4th quarter valued at approximately $56,000. Curi Wealth Management LLC boosted its stake in G1 Therapeutics by 37.9% during the 4th quarter. Curi Wealth Management LLC now owns 81,009 shares of the company’s stock valued at $440,000 after purchasing an additional 22,272 shares during the period. SG Americas Securities LLC boosted its stake in G1 Therapeutics by 22.6% during the 4th quarter. SG Americas Securities LLC now owns 47,047 shares of the company’s stock valued at $255,000 after purchasing an additional 8,684 shares during the period. Finally, Bank of Montreal Can bought a new stake in G1 Therapeutics during the 4th quarter valued at approximately $596,000. 53.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GTHX has been the subject of a number of recent research reports. EF Hutton Acquisition Co. I dropped their target price on G1 Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Monday, February 13th. JPMorgan Chase & Co. raised G1 Therapeutics from an “underweight” rating to a “neutral” rating and raised their price target for the company from $7.00 to $10.00 in a report on Monday, January 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of G1 Therapeutics in a report on Wednesday, April 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of G1 Therapeutics in a report on Thursday, March 2nd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, G1 Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.60.

G1 Therapeutics Stock Performance

Shares of GTHX opened at $2.69 on Friday. The stock has a market capitalization of $138.97 million, a P/E ratio of -0.97 and a beta of 1.93. The firm’s fifty day simple moving average is $2.77 and its two-hundred day simple moving average is $4.73. The company has a current ratio of 4.57, a quick ratio of 4.11 and a debt-to-equity ratio of 1.72. G1 Therapeutics, Inc. has a 12 month low of $2.38 and a 12 month high of $17.49.

G1 Therapeutics (NASDAQ:GTHX – Get Rating) last posted its earnings results on Wednesday, March 1st. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.12. The firm had revenue of $10.25 million for the quarter, compared to analysts’ expectations of $9.61 million. G1 Therapeutics had a negative net margin of 219.66% and a negative return on equity of 222.92%. As a group, analysts predict that G1 Therapeutics, Inc. will post -1.44 EPS for the current year.

G1 Therapeutics Company Profile

(Get Rating)

G1 Therapeutics, Inc engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.